Researchers from ACHUCARRO collaborate with CIC biomaGUNE in this work in the field of molecular imaging and neuroscience
Abraham Martín and Ana Joya, from the Laboratory of Neuroimaging and biomarkers of inflammation and Estibaliz Capetillo from the Laboratory of Neurobiology of ACHUCARRO are part of an international group of researchers led by Jordi Llop (CIC biomaGUNE, BRTA) that have just published a paper to advance in the diagnosis of Alzheimer's disease.
Edgar Soria-Gomez publishes this article in Neuron, started back in his postdoc in Bordeaux
The recreational and therapeutic uses of cannabinoid compounds are increasing around the world. They have been proposed to control pain sensitivity in clinical settings. However, due to significant side effects, such as cognitive impairments and motor dysfunctions, the medicinal exploitation of these drugs and the safety of their recreational use are under intense debate. The main psychoactive component of the cannabis sativa (marijuana) plant is delta-9 tetrahydrocannabinol or THC, which, in the brain, acts mainly by activating cannabinoid receptors type-1 (CB1). The pharmacological activation of the CB1 receptor affects motor control in experimental animals, while in humans the cataleptic effects are considered one of the main causes of traffic accidents due to cannabis use. Therefore, understanding the mechanisms of cannabinoid-induced therapeutic and adverse effects is vital for the safest use of these compounds, but the underlying cellular and molecular mechanisms are poorly understood.
Carlos Matuteri elkarrizketa, BERRIA aldizkarian
Jakes Goikoetxea kazetariak, ACHUCARROko Zuzedari Zientifikoa izandako, Carlos Matuteri egindako elkarrizketa ekartzen duzuegu hemen.
A review on their pathological significance and molecular pathways
This review article is fruit of the collaboration between different laboratories and researchers in Achucarro, with Dr. Pranav Preman at VIB-KU Leuven, Belgium.
Researcher from Institute Biofisika, CIC biomaGUNE and ACHUCARRO collaborate in this work in the field of molecular imaging
This article shows the results of an amazing collaboration that led to successfully prepare fluorine-labelled nanoparticles (NPs) that are active in 19F magnetic resonance imaging (19F MRI) by either conjugating four different fluorinated building blocks, shown in the 3D structure, to carboxyl-modified NPs or by direct grafting of PEG-fluorinated ligands. The research team obtained 19F MRI images of NPs accumulating in mice livers after intravenous injection.